Mineralocorticoid receptor activation and cardiac fibrosis

Area of Science:

• Cardiovascular Research
• Endocrinology
• Pathophysiology

Background:

• Mineralocorticoid receptor (MR) activation, via exogenous mineralocorticoids or endogenous glucocorticoids, induces oxidative stress and vascular inflammation.
• These early changes are implicated in the development of cardiac fibrosis in animal models.
• Recent clinical trials highlight cardioprotective benefits of MR antagonists in heart failure management.

Purpose of the Study:

• To explore the mechanisms underlying MR activation in the failing heart.
• To understand the role of MR in the pathogenesis of cardiac fibrosis.
• To identify novel therapeutic targets for heart failure.

Main Methods:

• Review of experimental animal studies on MR activation and cardiac fibrosis.
• Analysis of data from large-scale clinical trials of MR antagonists in heart failure.
• Investigation of potential non-aldosterone pathways for MR activation in cardiac disease.

Main Results:

• MR activation is linked to early-stage oxidative stress and vascular inflammation, preceding cardiac fibrosis.
• MR antagonists demonstrate significant cardioprotective effects in patients with moderate-to-severe heart failure.
• Elevated plasma aldosterone levels were not consistently observed in heart failure patients benefiting from MR antagonists.

Conclusions:

• MR activation contributes to the development of cardiac fibrosis through oxidative stress and inflammation.
• MR antagonists represent a valuable therapeutic strategy for heart failure.
• Novel mechanisms of MR activation in the failing heart, independent of high aldosterone, require further investigation.